Hillhouse Exits, Giants Consolidate: Mature Medical Device Sector Enters Consolidation Phase

Heart Future

May 22, 2026,Lifetech Scientific (01302.HK) announced a proposed acquisition of approximately 96.46% equity interest in Starway Medical Co. Ltd for approximately RMB 1.8733 billion., the seller is a holding platform under Hillhouse Capital, and the consideration is paid entirely in convertible bonds, with no cash involved.

This is a transaction where strategic intent far outweighs financial return—Lifetech uses a "promissory note" to bring a core competitor in China's congenital heart disease and PFO occluder market under its umbrella, while Hillhouse completes a classic "exchanging mature assets for liquidity" exit.

# Who is Starway Medical? What is Lifetech Scientific buying?

Starway Medical in2002Founded in Beijing in [Year], it isChinese Structural Heart Disease OccludersOne of the pioneers in the field, its history has closely paralleled the development of this niche market in China:

Starway Medical's core value is China's congenital heart disease occluder market's"`The Third`"Position. In China's congenital heart occluder market,Lifetech、Starway Medical、Shanghai Shape Memory(Subsidiary of Lepu Medical)The three companies collectively account for90%The above share. Lifetech Scientific's acquisition of Starway Medical means that the top two players in this market will merge into a single company.

# Why now, why this deal?？

(1) Why Is Hillhouse Exiting at This Time?

Hillhouse Capital's divestment from Starway Medical aligns with its recent consistent investment strategy. Since2025Since the second half of the year, Hillhouse Capital has repeatedly made significant divestitures in the mature asset sector, shifting its focus from"Invest Early, Invest in Innovation"Shift focus to the continuous revitalization of mature assets.

Starway Medical's annual profit is approximately1.75100 million yuan, valued at approximately19hundred million yuan, is a mature investment target with stable operations but plateauing growth potential, presenting a reasonable window for exit. Meanwhile, the two structural pressures facing Starway Medical are also intensifying: first, the pricing margins in the congenital heart disease (CHD) occluder market continue to narrow due to regional centralized procurement policies; second,PFOThe occluder market, along with AbbottAmplatzer Talisman 2024Since entering China in [year], the competitive landscape has been intensifying.

(II) Why Acquire Lifetech

Lifetech Scientific2024`annual revenue of approximately`13.59hundred million yuan, three main product lines covering structural heart disease (congenital heart defect occluders+Left atrial appendage occluder), peripheral vascular disease (covered stent+vena cava filters), pacing and electrophysiology. Among these, the structural heart disease business is the fastest-growing segment, and the acquisition of Starway Medical aptly reinforces this core strategic direction.

Specifically, what Lifetech stands to gain from this transaction:

• Structural Leap in Market Share：Integrating the previously competing domestic CHD occluders"Penis+Lao San"Merger, establishing stronger pricing power and channel control in this niche market.

• PFORapid Market Entry of the Occluder：Lifetech Scientific is currently inPFOThere are no mature commercialized products in the occluder field, while Starway Medical'sCardi-O-Fixis one of the only few in ChinaPFOOne of the occluder registration certificates.2022Year ChinaPFOThe number of interventional procedures has reached4With a volume of approximately 10,000 cases, it has surged to the top position among all structural heart disease interventions, and the growth momentum continues. This represents a rapidly expanding market segment that Lifetech had previously been largely absent from.

• Valuation Support from Comparable Companies：The comparable companies selected in the announcement include MicroPort Endovastec, Yingtai Medical, Procare Medical, Lepu Xintai, and APT Medical, with the average adjusted P/E ratio22.6times; Starway Medical with18The transaction was closed at a valuation multiple, providing a reasonable margin of safety for the buyer.

（3) CashlessTransaction Structure: Calculated Move or Reluctant Compromise?

What most warrants separate analysis in this transaction is the design of the consideration structure.——Lifetech issued convertible bonds to Hillhouse without any cash payment, at a conversion price of per share.2.5HKD (representing a premium of approximately over the closing price on the announcement date8.2%), bond term3Year, Annual Interest Rate3.5%, if not converted upon maturity, it may be redeemed, and the redemption price shall be [a percentage] of the principal1.5times or produce12.5%The higher of the two internal rates of return shall apply.

This means:

• Lifetech retained all its cash, mitigating the impact of the M&A on short-term operations.

• Hillhouse secured stable interest income through the bonds, and retained the right to2.5Hong Kong Dollar/Options to Convert Shares into Lifetech Scientific Shares

• If Lifetech's stock price is at3If it rebounds above the conversion price within the year, Hillhouse may choose to convert into shares to realize additional returns; if it falls short of expectations, then it shall...1.5times the principal or12.5% IRRCompensation Received

• Hillhouse also undertakes that, following the closing, at a price not exceeding2.5Hong Kong Dollar/at an average price per share, acquire additional issued shares of Lifetech to become the sole largest shareholder. This will fundamentally reshape Lifetech's shareholding structure and trigger Hillhouse's nomination rights for Lifetech's management.2Rights of the Executive Director.

# # The Value and Risks of the Transaction

Rationality of the Synergistic Logic

Lifetech and Starway Medical are highly complementary in product categories rather than completely overlapping.: Lifetech atASDdemonstrates significant advantages in occluders and left atrial appendage occluders, with Starway Medical inPFOThe occluder and certain congenital heart disease (CHD) occluder product categories have established independent brand recognition and clinical reputation. Both share the same procedural settings for structural heart interventions and hospital distribution channels, resulting in relatively low friction costs for channel integration.

Product Line Pressures Facing Starway Medical

In the announcement, it frankly admitted,Starway Medical's structural heart product line faces ongoing sales and procurement pressure.——This is the common predicament faced by all occluder manufacturers under the centralized procurement framework. There is currently no clear timetable regarding whether CHD occluders will be included in centralized procurement in China, although regional procurement initiatives already have precedents. Should such pressure intensify during the three-year bond period, it will impact Starway Medical's net profit, thereby affecting Lifetech Scientific's debt servicing capacity.

Uncertainty in Integration Execution

Starway Medical's Business Integration and Management SuccessionThis was listed in the announcement itself as one of the discount factors. Both companies maintain independent R&D systems, sales teams, and hospital market access networks; the stability of key personnel during the integration process will be the most critical variable at the execution level.

Long-Term Impact of Equity Dilution

If the convertible bonds are converted in full, approximately8.6100 million new shares, representing approximately of the current issued share capital15.66%。The dilution effect on Lifetech's existing shareholders must be taken into consideration; meanwhile, Hillhouse through increasing its stake+The share conversion arrangement is expected to result in the converting party becoming Lifetech's single largest shareholder, substantially impacting the company's corporate governance structure.

# DelayExtended Information and Role-Specific Research Recommendations

Supplementary Industry Background: China Structural Heart Disease Occluder Market

Congenital heart disease (CHD) occluders are the longest-established and most mature product category in China's structural heart disease sector. From a global perspective,Abbott (AGA/AmplatzerSeries)accounts for approximately55%Market share; in China,Lifetech Scientific, Starway Medical, Shape Memory (subsidiary of Lepu Medical)The three combined account for90%Given the above market share, the market has become highly localized.

PFOOccluders are currently the faster-growing sub-sector, in55among adults under the age of ,PFOThe prevalence of stroke among patients reaches as high as50%, with the growing awareness of cardiogenic stroke, demand for interventional closure is rapidly scaling up. From the perspective of the competitive landscape of registration certificates, as of2025Year3Month, only in China7ZhangPFOThe regulatory approval of the occluder registration certificate pertains to a product category that remains in an early stage of market penetration. By acquiring Starway Medical, Lifetech secured immediate entry into this sector, marking the most forward-looking strategic move of this transaction.

# Key Variables to Watch Next

• Approval Status of the Extraordinary General Meeting: This transaction constitutes a major transaction under the Listing Rules and is subject to shareholders' approval. The circular is expected to be2026Year6Month30Recently dispatched. Barring any significant objections, regulatory approval obstacles are limited.

• China Anti-Monopoly Review: One of the conditions precedent to closing is obtaining approval from the anti-monopoly review authority. Given the increased market concentration in the congenital heart defect occluder market post-merger, whether it will trigger a substantive review warrants attention.

• Developments at Jenscare Scientific: Jenscare Scientific had previously held approximately24.98%equity, upon completion of this transaction, Jenscare Scientific will hold approximately the remaining3.54%The equity disposal plan has not yet been disclosed, and its shareholding relationship with Lifetech Scientific warrants close attention.

• The Pace of Evolution of the Volume-Based Procurement Policy：If congenital heart disease occluders are included in China's centralized procurement during the three-year bond period, it will directly impact Starway Medical's profitability and indirectly affect the assessment of Lifetech Scientific's debt repayment capacity.

# What impact does this have on you, the viewer?

• CorrectSecondary Market Investors: Close attention should be directed to the complete financial details of Starway Medical disclosed in the circular (currently only profit data is available, with the asset-liability structure yet to be disclosed), the voting results of the Extraordinary General Meeting (EGM), and the pace of Hillhouse’s incremental stake acquisition in Lifetech Scientific to become its largest shareholder. The pricing of comparable companies, Lepu Hearttech and Aptmed, provides a reference framework for evaluating the post-acquisition valuation anchor of Lifetech Scientific.

• CorrectStrategic or ... of the Cardiovascular Device IndustryBDTeam: This case presents a zero-cash acquisition.+The structural framework of convertible bonds, under conditions of constrained buyer liquidity and relatively stable target asset valuations, represents a well-balanced arrangement that accommodates both the buyer's liquidity needs and the seller's exit requirements. It serves as a valuable structural reference for comparable transactions.

• CorrectFollowPFO/Clinicians in the congenital heart disease occluder sector orKOL: Should the integration between Lifetech and Starway Medical proceed smoothly, the consolidation of sales channels may lead to competition between the two companies' products within the same sales system, which could temporarily affect the hospital promotion pace for their respective products in the short term. In the medium term, a unified clinical support and training system has the potential to enhancePFOOverall penetration rate of occluders.

• CorrectEarly-stage investors in the structural heart disease sector: The signal conveyed by this transaction is——In mature product segments such as congenital heart disease (CHD) occluders, the window for industry consolidation has opened, and the M&A valuation of remaining independent players is being repriced. Notably, Shape Memory (a subsidiary of Lepu Medical), as another major player in the CHD occluder market, presents its trajectory regarding independence versus integration as the next key M&A question worthy of in-depth analysis.